Watson Pharmaceuticals, Inc. Company Valuation
Download
Report
Transcript Watson Pharmaceuticals, Inc. Company Valuation
Watson Pharmaceuticals, Inc.
Company Valuation
Sixuan Chen
Advanced Corporate Finance
Prof. Satya Gabriel
April. 11, 2006
Presentation Overview
Industry profile
Current situation: company profile
Forward looking: strategic plans
Business environment: customers and
competitors
Financial performance
Valuation (assumptions, merger analysis)
Industry Profile
Global sales: $300 billion annually
U.S. - largest market share, followed by
Europe and Japan
Brand drugs: customer loyalty, exclusive
rights
Generic drugs: bioequivalents, costefficient
Company Profile
Development, manufacture, marketing, sale
and distribution of brand and generic drugs
Fourth largest generic drugmaker by
market cap (after Teva, Barr and Mylan)
Key statistics:
Total revenue in 2005: $1.6 billion
Total assets1: $3.1 billion
Market cap2 : $3.2 billion
Footnote: 1: as of 12/31/2005
2: as of 4/3/2006
Generic vs. Brand segment
76% of total revenue
More than 125
generic products
47 ANDAs on file
Development in 2005:
six new launches
24% of total revenue
More than 20 brand
products
Two sales groups:
Specialty Products
Nephrology
Branded Product Pipeline
Branded
Product
Disease
Market
Alliance Status
SilodosinTM
Benign-Prostatic
Hyperplasia
Kissei
2nd Generation
Oxybutynin
Overactive
Bladder
Early Stage
Trelstar® line
extension
Urology
Early Stage
IntrinsaTM
Female Sexual
Dysfunction
P&G
Filed
EmSamTM
Depression
SomersetBMS
Approved
Late Stage
Strategic Alliances and
Collaborations
Somerset Pharmaceuticals, 50-50 JV with
Mylan (agreement w/ BMS)
Feb. 2006, FDA approval for Emsam®
Generics development alliance with Cipla
Citalopram (Q4, 2004)
R&D Capacity
R&D expense in 2005: $125.3 million (7.6% of
revenue)
R&D facilities:
Corona, California
Danbury, Connecticut
Copiague, New York
Salt Lake City, Utah
Malmo, Sweden
Changzhou, China
Strategic Plans
Generic:
Development of generic
drugs that are difficult to
formulate
Market generic alternatives
to brand products
Distribute generic versions
of third-party brands
“Watson Lab”, “Watson
Pharma”, “Rugby”
Brand:
2005 launches:
Trelstar® and Oxytrol®
Higher profit margin
Continue to expand through
Internal product
development
Strategic alliances and
acquisitions
Business Environment
High entry-barrier
Customers: drug wholesalers, retailers,
distributors
Consolidation in distribution network
Pricing pressure
Competitive Landscape
Brand products:
J&J, Novartis, Pfizer
No competitive advantage
Generic products
Teva, Barr, Mylan, brand name companies in
the generic market
Key: timing of product’s regulatory approval
and launch
Financial Performance
Revenue growth 5-year CAGR: 9.13%
In 2005, total revenue growth 0.34%
Generics: -2.51%
Brand: 4.37%
Price declines on nicotine gum due to entry of a
competitor
Increase in R&D expenses
Specialty - Trelstar®
Nephrology - Ferrlecit®
Impairment charge: $25.1 million (2005)
Stock Performance
Source: Datastream, Yahoo!-Finance
1-year Stock
Performance
WPI vs. Industry
1-year Stock
Performance
WPI vs. S&P 500
Source: Datastream, Yahoo!-Finance
Valuation – DCF
Key assumptions:
Operations:
Organic revenue growth
Gross/operating margin
CapEx, Depreciation
Working capital
Valuation – DCF (cont’d)
CAPM model:
Risk free rate: 4.86%
Market risk premium: 6.00%
Beta: 1.55
Default spread: 2.00% (Bond rating: BBB-)
Debt ratio: 15.47%
Tax rate: 37%
WACC = 12.65%
Valuation – DCF Result
5-year top-line growth: 6%
Continued growth: 5%
Price per share: $30.45
Current share price1: $29.01
Consensus estimates:
Valueline 3-5 year price range: $45-$65
Thompson 12-month target price: $32
1: Share price as of April 3, 2006
Valuation – DCF Sensitivity
Analysis
Continued growth rate
5-year top-line
growth
Management
9.25%
prediction
Valueline
6.00%
estimate
Worst-case
4.00%
estimate
6%
5%
4%
$34.91
$31.16
$28.27
$34.02
$30.45
$27.70
$33.37
$29.91
$27.26
Valuation – DCF Sensitivity
Analysis (cont’d)
Continued growth rate
WACC
6%
5%
4%
10%
$59.12
$48.62
$41.61
11%
$46.97
$40.21
$35.39
12%
$38.88
$34.22
$30.73
Valuation – Comps
Brand: Pfizer, J&J, Glaxosmithkline,
Novartis, Bayer
Generic: Teva, Barr, Mylan, King,
Alpharma, Par
Forward P/E1: $27.21
Forward Price/Sales1: $44.14
1: For both P/E and Price/Sales used Generic Median;
Sales and EPS estimates from Thompson One
Potential Merger Analysis
WPI agreed to acquire Andrx for $1.9
billion in cash ($25 per share, 32%
premium)
Andrx – Drug delivery
Total revenue in 2005: $1 billion
Total assets: $1.2 billion
Total market cap: $1.7 billion
Current P/E: 27.9x
Drug distribution (65%), manufacture (35%)
Potential Merger Analysis (cont’d)
Merger positives
Third-largest generic drug maker, 60 generic
drugs in pipeline
Synergies in SG&A
Distribution network
Merger negatives
Potential opposition
Creditwatch by S&P
Andrx production halted by FDA
SUMMARY
DCF valuation range: $27-35
Potential upside
Merger impact
Industry prospect: aging population
Recommendation: cautious buy at low
THANK YOU!
Questions?